Skip to main content

Research News

 

Clinical courses

  • Blocking proteins could pull the plug on power for colon tumors

    Through study findings published Friday in Cell Reports, a team of scientists at VCU Massey Cancer Center discovered a previously unknown interaction between proteins that is responsible for supplying energy to tumor cells and could hold significant implications for the development of future treatments for colon cancer.

  • Inflammatory signs for adolescent depression differ between boys and girls

    New research led by the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London has found that depression and the risk of depression are linked to different inflammatory proteins in boys and girls.

    When inflammation occurs in the body a host of proteins are released into the blood called cytokines. Previous research has shown that higher levels of cytokines are associated with depression in adults, but little is known about this relationship in adolescence.

  • AstraZeneca blood cancer medicine, Calquence approved in China

    AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in China for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy.

  • New genes and natural toxins offer hope for cancer patients unresponsive to chemotherapy

    Scientists from Queen Mary University of London have discovered two new genes that cause head and neck cancer patients to be resistant to chemotherapy, and that silencing either gene can make cancer cells previously unresponsive to chemotherapy subsequently respond to it.

    The two genes discovered actively ‘work’ in most human cancer types, meaning the findings could potentially extend to other cancers with elevated levels of the genes.

  • Researchers identify stem cells in the thymus for the first time

    Researchers at the Francis Crick Institute have identified stem cells in the human thymus for the first time. These cells represent a potential new target to understand immune diseases and cancer and how to boost the immune system.

  • Griffith on the cusp of a new vaccine modality breakthrough

    Griffith University researchers are on the brink of a technological breakthrough in vaccine development with a possible new vaccine modality. Professor Bernd Rehm and Dr Shuxiong Chen from the Griffith Institute for Drug Discovery (GRIDD) and Griffith’s Centre for Cell Factories and Biopolymers have succeeded in developing a new vaccine modality that is a stable particulate vaccine.

  • Study Uncovers Genetic Risk Factors for Heart Failure

    In a new study co-led by investigators at the United States Department of Veterans Affairs and Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system, a global team of scientists conducted one of the largest genetic association studies on heart failure to date. Using genomic data from over 90,000 heart failure patients and more than a million controls, the team identified 39 genetic mutations associated with heart failure, 18 of which had not been reported previously.

  • New antibiotic from microbial dark matter could be powerful weapon against superbugs

    Antimicrobial resistance is a major problem for human health and researchers worldwide are looking for new solutions. “We urgently need new antibiotics to combat bacteria that become increasingly resistant to most clinically used antibiotics,” says Dr. Markus Weingarth, a researcher from the Chemistry Department of Utrecht University.

  • Researchers fully Sequence the Y Chromosome for the First Time

    Led by the National Human Genome Research Institute (NHGRI), a team of researchers at the National Institute of Standards and Technology (NIST) and many other organizations used advanced sequencing technologies to read out the full DNA sequence of the Y chromosome a  region of the genome that typically drives male reproductive development.

  • FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

    The Food and Drug Administration granted regular approval to pralsetinib (Gavreto, Genentech, Inc.) for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Subscribe to Research News